| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
27,800,000 |
| Market
Cap: |
1.75(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.063 - $0.063 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ContraFect is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of antibiotic-resistant infections. Co.'s primary product candidate, exebacase, for the treatment of MRSA bloodstream infections (bacteremia), including right-sided endocarditis. In addition to bacteremia, Staphylococcus aureus is also a common cause of pneumonia and osteomyelitis as well as biofilm-associated infections of heart valves, indwelling devices and catheters. Co.'s product candidate, CF-370, is designed to target a gram -negative bacteria including Pseudomonas aeruginosa.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Messinger Michael |
Chief Financial Officer |
• – – |
2019-12-13 |
4 |
B |
$0.37 |
$1,850 |
D/D |
5,000 |
19,091 |
2.66 |
- |
|
| Sucoff Cary |
Director |
– • – |
2019-12-13 |
4 |
B |
$0.39 |
$19,500 |
D/D |
50,000 |
62,000 |
2.39 |
- |
|
| Low David N. |
Director |
– • – |
2019-12-13 |
4 |
B |
$0.43 |
$129,000 |
D/D |
300,000 |
370,550 |
2.39 |
- |
|
| Fosun Industrial Co., Ltd |
10% Owner |
– – • |
2018-12-04 |
4 |
S |
$2.04 |
$1,224,000 |
D/D |
(600,000) |
7,900,000 |
|
- |
|
| Shanghai Fosun Pharmaceutical (group) Co., Ltd. |
10% Owner |
– – • |
2018-12-04 |
4 |
S |
$2.04 |
$1,224,000 |
I/I |
(600,000) |
7,900,000 |
|
- |
|
| Shanghai Fosun Pharmaceutical (group) Co., Ltd. |
10% Owner |
– – • |
2017-07-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
8,500,000 |
|
- |
|
| Fosun Industrial Co., Ltd |
10% Owner |
– – • |
2017-07-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,500,000 |
|
- |
|
| Blech Isaac |
Director |
– • – |
2017-07-25 |
4 |
B |
$1.24 |
$19,840 |
D/D |
16,000 |
16,000 |
2.39 |
- |
|
| Sucoff Cary |
Director |
– • – |
2017-07-25 |
4 |
B |
$1.24 |
$14,880 |
D/D |
12,000 |
12,000 |
2.39 |
- |
|
| Barer Sol J |
Director |
– • – |
2017-07-25 |
4 |
B |
$1.24 |
$49,600 |
D/D |
40,000 |
815,933 |
2.39 |
- |
|
| Cassino Cara M |
Chief Medical Officer |
• – – |
2017-07-25 |
4 |
B |
$1.24 |
$9,920 |
D/D |
8,000 |
8,000 |
2.74 |
- |
|
| Muntner Joshua B |
SVP Business Development |
• – – |
2017-07-25 |
4 |
B |
$1.24 |
$2,480 |
D/D |
2,000 |
2,000 |
2.66 |
- |
|
| Messinger Michael |
SVP Finance |
• – – |
2017-07-25 |
4 |
B |
$1.24 |
$992 |
D/D |
800 |
14,091 |
2.66 |
- |
|
| Bogdanos Natalie |
General Counsel |
• – – |
2017-07-25 |
4 |
B |
$1.24 |
$992 |
D/D |
800 |
800 |
2.66 |
- |
|
| Ricciardi Lisa |
Director |
– • – |
2017-07-25 |
4 |
B |
$1.24 |
$11,904 |
D/D |
9,600 |
9,600 |
2.39 |
- |
|
| Otto Michael |
Director |
– • – |
2017-07-25 |
4 |
B |
$1.24 |
$9,920 |
D/D |
8,000 |
8,000 |
2.39 |
- |
|
| Pomerantz Roger |
Director |
– • – |
2017-07-25 |
4 |
B |
$1.24 |
$992 |
D/D |
800 |
800 |
2.31 |
- |
|
| Low David N. |
Director |
– • – |
2017-07-25 |
4 |
B |
$1.24 |
$49,600 |
D/D |
40,000 |
70,550 |
2.39 |
- |
|
| Gilman Steven C |
CEO |
• • – |
2017-07-25 |
4 |
B |
$1.24 |
$992 |
D/D |
800 |
20,800 |
2.73 |
- |
|
| Gilman Steven C |
CEO |
• • – |
2016-07-27 |
4 |
B |
$2.48 |
$49,600 |
D/D |
20,000 |
20,000 |
2.81 |
- |
|
| Couto Daniel |
SVP Manufacturing & Facilities |
• – – |
2015-11-17 |
4 |
AS |
$3.81 |
$10,937 |
D/D |
(2,872) |
0 |
|
- |
|
| Couto Daniel |
SVP Manufacturing & Facilities |
• – – |
2015-11-03 |
4 |
AS |
$4.23 |
$12,135 |
D/D |
(2,867) |
2,872 |
|
- |
|
| Couto Daniel |
SVP Manufacturing & Facilities |
• – – |
2015-10-20 |
4 |
AS |
$4.48 |
$12,854 |
D/D |
(2,867) |
5,739 |
|
- |
|
| Couto Daniel |
SVP Manufacturing & Facilities |
• – – |
2015-10-06 |
4 |
AS |
$4.11 |
$11,782 |
D/D |
(2,867) |
8,606 |
|
- |
|
| Couto Daniel |
SVP Manufacturing & Facilities |
• – – |
2015-09-22 |
4/A |
S |
$4.76 |
$13,644 |
D/D |
(2,867) |
11,473 |
|
- |
|
45 Records found
|
|
Page 1 of 2 |
|
|
